SavedAdd your journal

Journals / Clinical and Experimental Health Sciences / 2021 / Cilt: 11 - Sayı: 1

The Awareness and Knowledge of Dentists about Medication-Related Osteonecrosis of Jaws

Aylin EKMEKÇİOĞLU
Gülsün AKAY
Özge KARADAĞ
Kahraman GÜNGÖR
Pages
163–169
Publication Date
2021-03-31
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, MRONJ awareness among general dentists was poor.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Medication-related osteonecrosis of the jaw (MRONJ) is a serious condition affecting the quality of life of patients taking antiresorptive and anti-angiogenic drugs.
📊
Key Findings & Data:The questionnaire contained 20 questions on the demographic data of the participants and their awareness of MRONJ and the complications of antiresorptive or anti-angiogenic drugs.
💡
Conclusion & Impact:Overall, MRONJ awareness among general dentists was poor.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Antiresorptive · antiangiogenic · medications

Abstract

Objective: Medication-related osteonecrosis of the jaw (MRONJ) is a serious condition affecting the quality of life of patients taking antiresorptive and anti-angiogenic drugs. The main purpose of this study was to evaluate dentists’ awareness of MRONJ. Methods: A questionnaire was administered to dentists. The questionnaire contained 20 questions on the demographic data of the participants and their awareness of MRONJ and the complications of antiresorptive or anti-angiogenic drugs. The responses were analyzed using Pearson’s chi-square test and Fisher’s exact test. Results: In total, 141 dentists participated in the survey. Of these, 42.6% did not know about MRONJ. There was a statistically significant difference between specialist dentists and general dentists on the questions about the complications, effects, and usage of antiresorptive and anti-angiogenic drugs on necrosis formation (p<0.05). Dentists with less experience (seven years’<) were more knowledgeable about MRONJ (86.7%); compared to those with more than seven years’ clinical experience. Conclusions: This study showed that the knowledge level of dentists regarding the side effects of antiresorptive and anti-angiogenic medications is weak. Overall, MRONJ awareness among general dentists was poor.

🔖

Cite This Article

EKMEKÇİOĞLU, A., AKAY, G., KARADAĞ, Ö., GÜNGÖR, K. (2021). The Awareness and Knowledge of Dentists about Medication-Related Osteonecrosis of Jaws. Clinical and Experimental Health Sciences, Cilt: 11 - Sayı: 1, 163–169. https://ajindex.com/articles/481371

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (11)

  1. Referans1. Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaw – 2009 Update. Approved by the Board of Trustees January 2009. Aust Endod J 2009
  2. 35(3):119-30. Referans2. Gomez Font R, Martinez Garcia ML, Olmos Martinez JM. Osteochemonecrosis of the jaws due to bisphosphonate treatments. Update. Med Oral Patol Oral Cir Bucal 2008
  3. 13(5):318-24. Referans3. Raj DV, Abuzar M, Borromeo GL. Bisphosphonates, healthcare professionals and oral health. Gerodontology 2016
  4. 33(1):135-43. Referans4. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O’Ryan F, American Association of Oral and Maxillofacial Surgeons. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg 2014
  5. 1938–1956. Referans5. Crépin S, Laroche ML, Sarry B, Merle L. Osteonecrosis of the jaws induced by clodronate, an alkyl bisphosphonate: case report and literature review. Eur J Clin Pharmacol 2010
  6. 66 (6):547-554. Referans6. Ristow O, Otto S, Troeltzsch M, Hohlweg-Majert B, Pautke C. Treatment perspectives for medication-related osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg 2015
  7. 43(2):290-3. Referans7. Tanna N, Steel C, Stagnell S, Bailey E. Awareness of medication related osteonecrosis of the jaws (MRONJ) amongst general dental practitioners. Br Dent J 2017
  8. 27(2):121-125. Referans8. Fleisher KE, Kontio R, Otto S. Antiresorptive drug-related osteonecrosis of the jaw (ARONJ) – a guide to research. Davos Platz (Switzerland): AO Foundation
  9. Available at: Referans9. Yazdi PM, Schiodt M. Dentoalveolar trauma and minor trauma as precipitating factors for medication-related osteonecrosis of the jaw (ONJ): a retrospective study of 149 consecutive patients from the Copenhagen ONJ Cohort. Oral Surg Oral Med Oral Pathol Oral Radiol 2015
  10. 119(4):416–22. Referans10. Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schiødt M. Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 2018
  11. 177–187. Referans11. De Lima PB, Brasil VLM, Castro JFL, de Moraes Ramos-Perez FM, Alves FA, dos Anjos Pontual ML, et al. Knowledge and attitudes of Brazilian dental students and dentists regarding bisphosphonate-related osteonecrosis of the jaw. Support Care Cancer 2015